SimBioSys and Ferrum Health Partner to Expand Access to AI Surgical Planning Tools

Jul 23, 2026
SimBioSys has partnered with Ferrum Health to make its FDA-cleared TumorSight Viz platform available through Ferrum's Model Hub, improving deployment and management of AI surgical planning capabilities across U.S. health systems.

SimBioSys has partnered with Ferrum Health to broaden access to its FDA-cleared TumorSight Viz platform through Ferrum's Model Hub, announced in a press release.

TumorSight Viz converts standard breast MRI scans into patient-specific 3D visualizations to assist surgeons in planning procedures. Through integration with Ferrum’s Model Hub, hospitals can deploy and manage the tool within existing infrastructure, enabling centralized oversight, monitoring, and scalability across clinical environments.

Ferrum’s platform supports the deployment of AI applications across healthcare systems, while TumorSight Viz brings a focus on breast surgical planning by generating anatomy-specific visualizations. The companies intend to accelerate access to these AI tools in more institutions, enhancing the ability of surgeons to make informed, context-rich decisions during surgical planning.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.